Thursday, February 21, 2013
This week in therapeutics
Publication and contact
growth factor receptor 3 (EGFR3;
Cell culture and mouse
studies suggest Zelboraf
could be used to treat BRAF-mutant thyroid cancer. In a thyroid cancer cell
line, vemurafenib activated HER3, which could be blocked with lapatinib. In
three BRAF-mutant thyroid cancer cell lines, vemurafenib plus lapatinib
decreased cellular proliferation compared with either drug alone. In a
genetic mouse model of thyroid tumorigenesis, combined treatment with the two
drugs decreased tumor volume compared with either drug alone. Ongoing work
includes clinical testing of the combination in individuals with metastatic
Sankyo Co. Ltd., Chugai
Pharmaceutical Co. Ltd. and Roche
market Zelboraf, an oral small molecule inhibitor of oncogenic BRAF V600E, to
treat melanoma. The drug is in Phase II testing for thyroid cancer.
plc markets Tykerb, a HER1
receptor kinase inhibitor, to treat breast cancer.
Published online Feb. 21, 2013
status not applicable
Montero-Conde, C. et al.
Cancer Discov.; published online Jan. 29, 2013;
Contact: James A. Fagin, Memorial Sloan-Kettering Cancer
New York, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]